 MediWound Ltd NASDAQ: MDWD has initiated a Phase 12 study of MW005 to treat low-risk Basal Cell Carcinoma BCC. In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma skin cancers is being conducted at the Soroka Medical Center in Israel. 